A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases

被引:278
作者
Hasle, H [1 ]
Niemeyer, CM
Chessells, JM
Baumann, I
Bennett, JM
Kerndrup, G
Head, DR
机构
[1] Skejby Sygehus, Dept Pediat, DK-8200 Aarhus N, Denmark
[2] Univ Freiburg, Childrens Hosp, Freiburg, Germany
[3] Inst Child Hlth, London, England
[4] Univ Erlangen Nurnberg, Inst Pathol, D-8520 Erlangen, Germany
[5] Univ Rochester, Ctr Canc, Rochester, NY USA
[6] Odense Univ Hosp, Inst Pathol, DK-5000 Odense, Denmark
[7] Vanderbilt Univ, Dept Pathol, Nashville, TN USA
关键词
myelodysplastic syndrome (MDS); juvenile myelomonocytic leukemia (JMML); Down syndrome; children; diagnostic criteria; classification;
D O I
10.1038/sj.leu.2402765
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Myelodysplastic and myeloproliferative disorders are rare in childhood and there is no widely accepted system for their diagnosis and classification. We propose minimal diagnostic criteria and a simple classification scheme which, while based on accepted morphological features and conforming with the recent suggestions of the WHO, allows for the special problems of myelodysplastic diseases in children. The classification recognizes three major diagnostic groups: (1) juvenile myelomonocytic leukemia (JMML), previously named chronic myelomonocytic leukemia (CMML) or juvenile chronic myeloid leukemia (JCML); (2) myeloid leukemia of Down syndrome, a disease with distinct clinical and biological features, encompassing both MDS and AML occurring in Down syndrome; and (3) MDS occurring both de novo and as a complication of previous therapy or pre-existing bone marrow disorder (secondary MDS). The main subtypes of MDS are refractory cytopenia (RC) and refractory anemia with excess of blasts (RAEB). It is suggested retaining the subtype of RAEB-T with 20-30% blasts in the marrow until more data are available. Cytogenetics and serial assessments of the patients are essential adjuncts to morphology both in diagnosis and classification.
引用
收藏
页码:277 / 282
页数:6
相关论文
共 47 条
[11]   Significance of p53 overexpression in bone marrow biopsies from patients with bone marrow failure: aplastic anemia, hypocellular refractory anemia, and hypercellular refractory anemia [J].
Elghetany, MT ;
Vyas, S ;
Yuoh, G .
ANNALS OF HEMATOLOGY, 1998, 77 (06) :261-264
[12]  
Elghetany MT, 1997, HAEMATOLOGICA, V82, P21
[13]   Myelodysplasia and myeloproliferative disorders in childhood: An update [J].
Emanuel, PD .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 (04) :852-863
[14]   APASTIC ANEMIA AND THE HYPOCELLULAR MYELODYSPLASTIC SYNDROME - HISTOMORPHOLOGICAL, DIAGNOSTIC, AND PROGNOSTIC FEATURES [J].
FOHLMEISTER, I ;
FISCHER, R ;
MODDER, B ;
RISTER, M ;
SCHAEFER, HE .
JOURNAL OF CLINICAL PATHOLOGY, 1985, 38 (11) :1218-1224
[15]  
Gamis AS, 2001, BLOOD, V98, p720A
[16]   International scoring system for evaluating prognosis in myelodysplastic syndromes [J].
Greenberg, P ;
Cox, C ;
LeBeau, MM ;
Fenaux, P ;
Morel, P ;
Sanz, G ;
Sanz, M ;
Vallespi, T ;
Hamblin, T ;
Oscier, D ;
Ohyashiki, K ;
Toyama, K ;
Aul, C ;
Mufti, G ;
Bennett, J .
BLOOD, 1997, 89 (06) :2079-2088
[17]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333
[18]   A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada [J].
Hasle, H ;
Wadsworth, LD ;
Massing, BG ;
McBride, M ;
Schultz, KR .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (04) :1027-1032
[19]   Risks of leukaemia and solid tumours in individuals with Down's syndrome [J].
Hasle, H ;
Clemmensen, IH ;
Mikkelsen, M .
LANCET, 2000, 355 (9199) :165-169
[20]  
Hasle H, 2001, BLOOD, V98, p624A